6:15 PM
 | 
Aug 26, 2009
 |  BC Extra  |  Clinical News

Acyclovir misses herpes endpoint

BioAlliance Pharma S.A. (Euronext:BIO) said a single 50 mg dose of acyclovir Lauriad ( BA-021) missed the primary endpoint of significantly decreasing time...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >